# Fudan University Shanghai Cancer Center

Source: https://onco.cc/institutions/fuscc/  
OnCo record `fuscc` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Fudan University Shanghai Cancer Center is China's leading breast cancer centre and the site of first-in-human TROP2 PET imaging.

## Summary

Fudan University Shanghai Cancer Center is China's leading breast cancer centre, ranked fifty-fifth in the Newsweek/Statista oncology list, and the site of the first-in-human TROP2 PET imaging study. Shao Zhimin's molecular subtyping of triple-negative breast cancer and the FUTURE umbrella trial built on it, the gallium-68 TROP2 nanobody PET tracer from Shaoli Song, and the highest breast cancer surgical volume in the world are its distinguishing contributions, with Yi-Zhou Jiang, Xichun Hu and Dingwei Ye also listed. OnCo links it to triple-negative breast cancer, to TROP2 as a target and TROP2 PET as a technology, and to Zhongshan Hospital and the Chinese Society of Clinical Oncology. Whether subtype-directed treatment of TNBC improves on a single standard is the question FUTURE was designed to answer. Its TNBC, TROP2 PET and surgery programmes are listed below.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Shanghai, CN
- Type: cancer-center
- Website: https://www.shca.org.cn

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Shanghai_Cancer_Center
- Official website: https://www.shca.org.cn
- PTCOG: particle therapy facilities in operation: https://www.ptcog.site/index.php/facilities-in-operation-public

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Carbon-ion synchrotrons and facilities](https://onco.cc/technologies/carbon-ion-synchrotrons/), [Carbon-ion therapy](https://onco.cc/technologies/carbon-ion/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/), [TROP2 PET](https://onco.cc/technologies/trop2-pet/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [FDA018-ADC](https://onco.cc/drugs/fda018-adc/)
- people: [Dingwei Ye](https://onco.cc/people/ye-dingwei/), [Jin Li](https://onco.cc/people/li-jin-fuscc/), [Shaoli Song](https://onco.cc/people/song-shaoli/), [Xichun Hu](https://onco.cc/people/hu-xichun/), [Yi-Zhou Jiang](https://onco.cc/people/jiang-yi-zhou/), [Zhi-Ming Shao](https://onco.cc/people/shao-zhi-ming/)
- institutions: [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [National Medical Products Administration / Center for Drug Evaluation](https://onco.cc/institutions/nmpa-cde/), [Zhongshan Hospital, Fudan University](https://onco.cc/institutions/zhongshan-hospital-fudan/)
- trials: [FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct06519370/)

---
JSON: https://onco.cc/api/v1/entities/fuscc.json